Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 11/20 | 0.83 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.83 |
| ▸ | FYN | P06241 | 3/20 | 0.68 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.61 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.61 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.61 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | IKBKB | O14920 | 5/20 | 0.58 |
| ▸ | CHUK | O15111 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2950857 | 0.91 | PIM1 (1.00) | PIM1PIM2FYNKCNH2IKBKB | |
| SCHEMBL2943175 | 0.91 | PIM1 (0.81) | PIM1PIM2FYNKCNH2IKBKB | |
| SCHEMBL2947771 | 0.87 | PIM1 (1.00) | PIM1PIM2FYNIKBKBCHUK | |
| SCHEMBL2943900 | 0.86 | PIM1 (0.75) | PIM1PIM2FYNIKBKBCHUK | |
| SCHEMBL2948202 | 0.85 | FYN (0.74) | PIM1PIM2FYNKCNH2 | |
| SCHEMBL2945011 | 0.83 | FYN (0.71) | PIM1PIM2FYNKCNH2 | |
| SCHEMBL2949543 | 0.83 | PIM1 (0.79) | PIM1PIM2FYNDYRK3DYRK1A | |
| SCHEMBL1049258 | 0.82 | FYN (0.83) | PIM1PIM2FYNDYRK3DYRK1A | |
| SCHEMBL1054075 | 0.81 | PIM1 (0.74) | PIM1FYNDYRK3DYRK1ADYRK2 | |
| SCHEMBL137404 | 0.81 | PIM1 (0.84) | PIM1PIM2FYNKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | MAP4K2, MAP3K1, MAP3K2 | PIM1 365/4885PIM2 294/4885FYN 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.